Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse glial tumor which infiltrates the brain extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted from WHO.)
Biomarker and diagnostic research for gliomatosis cerebri has been reported in the published literature.
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE1. Research is primarily industry-sponsored.
211 publications have been identified in PubMed for gliomatosis cerebri. Research spans Basic Science / Preclinical (34%), Review / Meta-Analysis (33%), and Gene Therapy / Novel Therapeutics (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 71 | 34% |
Data assembled from 4 of 12 sources · Last updated Oct 3, 2026, 8:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
70 |
33% |
New treatment approaches | 23 | 11% |
Patient case studies | 17 | 8% |
Disease patterns and progression | 13 | 6% |
Testing and diagnosis research | 11 | 5% |
Clinical study results | 6 | 3% |
Li J (2026). [PMID: 41957020](https://pubmed.ncbi.nlm.nih.gov/41957020/). *Nat Commun*. [Basic Science / Preclinical]
Ha J (2026). [PMID: 41803138](https://pubmed.ncbi.nlm.nih.gov/41803138/). *Nat Commun*. [Basic Science / Preclinical]
Zhang J (2026). [PMID: 41882358](https://pubmed.ncbi.nlm.nih.gov/41882358/). *Nature*. [Basic Science / Preclinical]
Wang Y (2026). [PMID: 41880493](https://pubmed.ncbi.nlm.nih.gov/41880493/). *Sci Adv*. [Gene Therapy / Novel Therapeutics]
Amezquita-Contreras C (2026). [PMID: 41926870](https://pubmed.ncbi.nlm.nih.gov/41926870/). *J Clin Neurosci*. [Epidemiology / Natural History]
Lindner M (2026). [PMID: 41828493](https://pubmed.ncbi.nlm.nih.gov/41828493/). *Int J Mol Sci*. [Review / Meta-Analysis]
Okuno H (2026). [PMID: 41821381](https://pubmed.ncbi.nlm.nih.gov/41821381/). *Am J Surg Pathol*. [Diagnostic / Biomarker]
Wang Y (2026). [PMID: 41796847](https://pubmed.ncbi.nlm.nih.gov/41796847/). *Cancer Lett*. [Review / Meta-Analysis]
Ichinose T (2026). [PMID: 41874002](https://pubmed.ncbi.nlm.nih.gov/41874002/). *JCI Insight*. [Basic Science / Preclinical]
Wang W (2026). [PMID: 41823537](https://pubmed.ncbi.nlm.nih.gov/41823537/). *Int J Oncol*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning gliomatosis cerebri
Updated Sep 2, 2026
A recent study published in PubMed explores diffuse high-grade glioma with a gliomatosis cerebri pattern, which can mimic symmetric white matter disease. This research contributes to the understanding of glioma presentations and may impact diagnostic approaches.